Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAK-PD1: Defactinib and Pembrolizumab in Advanced Solid Tumors
NCT02758587Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jul 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of defactinib in non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and mesothelioma (4 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Adverse events at 6 months. Status: unknown.
02
Drugs
defactinib
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)mesothelioma
Beyond the preview
Go deeper on NCT02758587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02758587.